Horizon Therapeutics’ Daxdilimab Phase 2 trial fails to reach primary endpoint in SLE

Horizon Therapeutics’ Daxdilimab Phase 2 trial fails to reach primary endpoint in SLE

Horizon Therapeutics plc (Nasdaq: HZNP) announced that its Phase 2 clinical trial studying the efficacy of daxdilimab in the treatment of systemic lupus erythematosus (SLE) did not achieve a statistically significant difference between daxdilimab and a placebo in reaching the primary endpoint. The primary measure was the proportion of patients achieving a British Isles Lupus […]

Amgen to acquire Irish biopharma company Horizon Therapeutics for $28bn

Amgen to acquire Irish biopharma company Horizon Therapeutics for $28bn

Amgen through its wholly-owned subsidiary Pillartree has agreed to acquire Ireland-based biopharmaceutical firm Horizon Therapeutics for an enterprise value of around $28.3bn. The US biotechnology company will pay $116.5 per share in cash, which is a premium of around 19.7% to Horizon Therapeutics’ closing stock price of $97.29 per share on 9 December 2022. Horizon […]

Glenmark Pharmaceuticals gets FDA final approval for Buphenyl generic

Glenmark Pharmaceuticals gets FDA final approval for Buphenyl generic

Glenmark Pharmaceuticals said that it has bagged final approval for Sodium Phenylbutyrate Tablets USP, 500 mg by the US Food and Drug Administration (FDA). The approved product is a generic version of Buphenyl Tablets (sodium phenylbutyrate), 500 mg, of Horizon Therapeutics and is indicated for the treatment of urea cycle disorders. According to Glenmark Pharmaceuticals, […]

Horizon Therapeutics to acquire Viela Bio for $3bn to grow rare disease portfolio

Horizon Therapeutics to acquire Viela Bio for $3bn to grow rare disease portfolio

Horizon Therapeutics, an Irish biopharma company, has agreed to acquire Viela Bio, a US-based biotech company, for $53 per share in cash or about $3.05 billion in a move to significantly expand its development pipeline and grow its rare disease medicine portfolio. Viela Bio is focused on developing and commercializing therapies for a wide variety […]